Bryn Mawr Trust CO Biogen Inc. Transaction History

Bryn Mawr Trust CO

8 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q2 2021 Jul 29, 2021	SELL	$259.0 - $414.71 $676,508 - $1.08 Million	-2,612 Closed	0 $0
Q1 2021 Apr 23, 2021	SELL	$242.95 - $284.63 $5,101 - $5,977	-21 Reduced 0.8%	2,612 $731,000
Q4 2020 Feb 11, 2021	SELL	$236.26 - $355.63 $215,232 - $323,978	-911 Reduced 25.71%	2,633 $645,000
Q2 2020 Aug 13, 2020	SELL	$258.66 - $342.55 $5,173 - $6,851	-20 Reduced 0.56%	3,544 $948,000
Q1 2020 May 08, 2020	BUY	$268.85 - $341.04 $958,181 - $1.22 Million	3,564 New	3,564 $1.13 Million
Q1 2019 May 15, 2019	SELL	$216.71 - $338.96 $144,978 - $226,764	-669 Closed	0 $0
Q4 2018 Feb 15, 2019	BUY	$278.5 - $352.75 $12,532 - $15,873	45 Added 7.21%	669 $201,000
Q3 2018 Nov 15, 2018	BUY	$293.51 - $383.83 $183,150 - $239,509	624 New	624 $220,000

1,018

128M

1.22M

1.4M

Ticker BIIB
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 144,000,992
Market Cap $25B
Description
Biogen Inc. discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases. The company offers TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; and FUMADERM to treat plaque psoriasis. It also provides BENEPALI, an eta...

Get notified when there are updates to the investment portfolio of Bryn Mawr Trust CO, based on Form 13F filings with the SEC.

Stay updated on Bryn Mawr Trust CO with notifications on news.